Printer Friendly

New Molecule to Target in Pancreatic Cancer Treatment.

Summary: TEHRAN (FNA)- Researchers identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases.

The findings Researchers at Mayo Clinic in Florida were published in the online issue of PLOS ONE.

The researchers decoded a molecular pathway that is switched "on" at all times, promoting accelerated growth of pancreatic tumors, and that discovery revealed ways to disable the pathway. They say one strategy could involve the use of the drug bortezomib, which is already approved for several human blood cancers.

"Targeting this pathway to decrease the proliferation of cancer cells may represent a new strategy for pancreatic cancer therapy," said the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic.

One feature of pancreatic cancer is increased activity of the transcription factor NF-kB, which turns on expression of genes that keep the cells proliferating and protect them from death. There are two pathways, known as the classical and alternative, by which NF-kB can be activated, and the researchers looked at the alternative pathway - one in which NF-kB is activated differently, and which switches on other genes, compared to the classical signaling pathway. Both the classical and alternative pathways are active in pancreatic cancer.

The research team discovered that increased activity of the alternative NF-kB pathway results from suppression of TNF receptor-associated factor 2, or TRAF2. Loss of TRAF2 promotes fast growth of pancreatic tumors and correlates with increased aggressiveness, Dr. Storz said.

They tested this discovery in 55 human samples of pancreatic cancer, and found that in 69 percent, TRAF2 wasn't functioning properly and there were higher levels of other molecules participating in the alternative pathway

.

A cocktail of drugs that includes chemotherapy, bortezomib and other inhibitors of molecules activated along the pathway may help pancreatic cancer patients, Dr. Storz said.

"Of course, this hypothesis requires extensive clinical testing, but our findings offer a new direction to investigate in improving treatment of pancreatic cancer," he added.

2012 Fars News Agency. All rights reserved

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2013 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:FARS News Agency
Date:Jan 4, 2013
Words:350
Previous Article:Mild Quake Hits Northwestern Iran.
Next Article:Stem Cells Used to Pinpoint Cause of Common Type of Sudden Cardiac Death.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters